Praxis Precision Medicines Inc. (PRAX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Praxis Precision Medicine... (PRAX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

66.00

1.98 (3.09%)

At close: Jan 14, 2025, 3:59 PM

65.84

-0.24%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	66
Market Cap	1.23B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-9.17
PE Ratio (ttm)	-7.2
Forward PE	n/a
Analyst	Buy

Ask	72
Volume	252,025
Avg. Volume (20D)	334,175
Open	65.30
Previous Close	64.02
Day's Range	64.26 - 67.87
52-Week Range	33.01 - 86.93
Beta	undefined

About PRAX

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhib...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 16, 2020

Employees 82

Stock Exchange NASDAQ

Ticker Symbol PRAX

Website https://www.praxismedicines.com

Analyst Forecast

According to 9 analyst ratings, the average rating for PRAX stock is "Buy." The 12-month stock price forecast is $150, which is an increase of 127.27% from the latest price.

Buy 88.89%

Hold 11.11%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Praxis Precision Medicines Inc. is scheduled to release its earnings on Mar 4, 2025, before market opens.
Analysts project revenue of $365.00K, reflecting a -29.13% YoY shrinking and earnings per share of -2.82, making a -5.05% decrease YoY.

Why Price Moved

9 months ago · Source

+23.13%

Praxis Precision Medicines shares are trading high... Unlock content with Pro Subscription

News

2 months ago · seekingalpha.com

Praxis Precision Medicines, Inc. (PRAX) Q3 2024 Earnings Call Transcript

Praxis Precision Medicines, Inc. (NASDAQ:PRAX ) Q3 2024 Earnings Conference Call November 6, 2024 8:00 AM ET Company Participants Dan Ferry - IR, LifeSci Communications Marcio Souza - President & CEO ...

2 months ago · zacks.com

Praxis Precision Medicines, Inc. (PRAX) Reports Q3 Loss, Misses Revenue Estimates

Praxis Precision Medicines, Inc. (PRAX) came out with a quarterly loss of $2.75 per share versus the Zacks Consensus Estimate of a loss of $2.01. This compares to loss of $2.70 per share a year ago.